Influenza virus ISCOMs: antibody response in animals.

This research article investigates the efficiency of a novel ISCOM vaccine, compared to traditional vaccines, in inducing an immune response against the influenza virus in different animal models.

Introduction and Objectives

• The study focused on the preparation and testing of an experimental ISCOM (Immunostimulating Complex) vaccine for influenza. These vaccines were created using the envelope glycoproteins haemagglutinin and neuraminidase from the equine strain, A/Solvalla/79 (H3N8).
• The primary objective was to compare the induced immune response by the ISCOM vaccine to that by a micelle vaccine and a conventional whole virus vaccine within different animal models – BALB/c mice, Guinea Pigs, and horses.

Methodology and Findings

• In vaccination trials performed on BALB/c mice, it was observed that the experimental ISCOM vaccine could induce serum antibody levels at least ten times higher than the micelle vaccine when measured using ELISA, a test used to measure the level of antibodies in a sample.
• When the trials were conducted on guinea pigs, the ISCOM vaccine showcased a tenfold increase in haemagglutination inhibition (HI) and neuraminidase inhibition (NI) titres in comparison to the micelle and whole virus vaccines. HI and NI titres reflect the amount of antibodies present that can halt the virus from infecting cells.
• Horses were tested with a divalent experimental ISCOM vaccine carrying equine strains A/Prague/56 (H7N7) and A/Solvalla/79 (H3N8). The findings indicated that this vaccine provoked an immune response that lasted much longer with higher antibody titres than horses immunized with the conventional whole virus vaccine.
• Lastly, the ISCOM vaccine managed to generate complete immunoprotection within mice when administered in a dose containing 1 microgram of envelope glycoproteins of the mouse pathogenic strain A/PR/8/34 (H1N1).

Conclusion

• The findings from this study strongly suggest the potential of ISCOM vaccines to provoke a substantially stronger and durable immune response than traditional vaccines.
• While it has been successfully used in varying animal models, further trials and explorations are required to determine its effectiveness across a broader spectrum and its potential usage in human models.